CIK 0001359931 · Non-accelerated filer<br>Smaller reporting company
Protara Therapeutics, Inc.
Sign in to watch- Ticker
- TARA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 204580525
- Phone
- 646-844-0337
- Business address
- 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK, NY, 10010
- Former names
- Protara Therapeutics, Inc., ArTara Therapeutics, Inc., PROTEON THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-30 | Shefferman Jesse CEO and President | Gift | −14,000 | 707,832 | ||
| 2026-06-30 | Shefferman Jesse CEO and President | Gift | −7,000 | 700,832 | ||
| 2026-06-30 | Shefferman Jesse CEO and President | Gift | −4,000 | 696,832 | ||
| 2026-06-30 | Shefferman Jesse CEO and President | Gift | −5,000 | 691,832 | ||
| 2026-06-29 | Shefferman Jesse CEO and President | Option exercise | +215,687 | $1.91 | $412K | 937,519 |
| 2026-06-29 | Shefferman Jesse CEO and President | Sale | −215,687 | $4.09 | $882K | 721,832 |
| 2026-06-29 | Shefferman Jesse CEO and President | Option exercise · Stock Option (Right to Buy) | −215,687 | 141,313 | ||
| 2026-06-15 | Levy Richard S Director | Grant or award · Stock Option (Right to Buy) | +31,000 | 31,000 | ||
| 2026-06-15 | Solomon Michael Edward Director | Grant or award · Stock Option (Right to Buy) | +31,000 | 31,000 | ||
| 2026-06-15 | Smith Cynthia Director | Grant or award · Stock Option (Right to Buy) | +31,000 | 31,000 | ||
| 2026-06-15 | SARGEN GREGORY Director | Grant or award · Stock Option (Right to Buy) | +31,000 | 31,000 | ||
| 2026-06-15 | Huang Jane Director | Grant or award · Stock Option (Right to Buy) | +31,000 | 31,000 | ||
| 2026-06-15 | GARCEAU ROGER Director | Grant or award · Stock Option (Right to Buy) | +31,000 | 31,000 | ||
| 2026-06-15 | Flannelly Barry P Director | Grant or award · Stock Option (Right to Buy) | +31,000 | 31,000 | ||
| 2026-06-15 | BESHAR LUKE M Director | Grant or award · Stock Option (Right to Buy) | +31,000 | 31,000 | ||
| 2026-06-02 | CONKLING WILLIAM Chief Commercial Officer | Shares withheld for taxes | −6,008 | $4.34 | $26K | 69,992 |
| 2026-04-08 | Zummo Jacqueline Chief R&D Officer | Sale | −1,134 | $5.40 | $6K | 94,827 |
| 2026-04-01 | Zummo Jacqueline Chief R&D Officer | Sale | −22,598 | $5.26 | $119K | 95,961 |
| 2026-01-26 | Shefferman Jesse CEO and President | Shares withheld for taxes | −8,732 | $6.67 | $58K | 1,021,832 |
| 2026-01-26 | Zummo Jacqueline Chf Scientific Operations Off | Shares withheld for taxes | −3,724 | $6.67 | $25K | 118,559 |
Page 1 of 8 · 154 trades